



Everyday people with acid reflux disease can now have new LOSEC 10mg Capsules as maintenance therapy.

LOSEC 10mg od gives a higher remission rate,<sup>1</sup> at a lower cost, than ranitidine 150mg bd. Making it no surprise that LOSEC is taking care of more and more people. Every day.

# EVERYDAY PEOPLE TAKE LOSEC

**NEW**  **LOSEC® 10mg**  
(omeprazole-Astra) **Capsules**

**LOSEC® CAPSULES (omeprazole) ABBREVIATED PRESCRIBING INFORMATION** (refer to full data sheet before prescribing) **PRESENTATION:** LOSEC Capsules containing 10mg, 20mg or 40mg omeprazole as enteric coated granules with an aqueous based coating. **USES:** Oesophageal reflux disease. Duodenal and benign gastric ulcers (including NSAID-induced). Duodenal ulcer associated with *Helicobacter pylori*. Zollinger-Ellison syndrome. **DOSAGE & ADMINISTRATION: Adults (including the elderly):** The usual dose in oesophageal reflux disease and peptic ulcer is 20mg once daily, increasing to 40mg once daily in severe or refractory cases, if required. **Oesophageal reflux disease:** Healing: 20mg daily for 4 weeks. Continue for further 4-8 weeks if required. **Maintenance in acid reflux disease:** LOSEC 10mg daily. Increase to 20mg daily if symptoms return. **Duodenal ulcer (DU):** Healing: 20mg daily for 4 weeks. **DU maintenance:** LOSEC 10mg daily increasing to 20mg daily if symptoms return. **DU associated with Helicobacter pylori:** Usual dose is LOSEC 40mg daily with amoxycillin 1.5g daily (750mg b.d.) for 2 weeks. Up to 2g/day of amoxycillin has been used in clinical studies. **Benign Gastric Ulcer:** 20mg daily for 8 weeks. **Zollinger-Ellison Syndrome:** 60mg daily as long as clinically indicated. Individually adjust within range

20-120mg daily. If in excess of 80mg daily give in 2 equal divided doses. **Renal impairment:** No dose adjustment needed. **Hepatic impairment:** Adjust dose (maximum daily dose 20mg). **Children:** No experience of use. **CONTRA-INDICATIONS, WARNINGS, ETC:** No known contra-indications. In gastric ulcer, exclude malignancy before starting therapy. Avoid in pregnancy unless no safer alternative. Discontinue breast feeding if LOSEC is considered essential. **Side effects:** LOSEC is well tolerated. Adverse reactions are generally mild and reversible (relationship to LOSEC not established in many cases). They include diarrhoea, headaches, skin disorders and in isolated cases, angioedema, musculoskeletal disorders, fatigue, insomnia, dizziness, blurred vision, vertigo, paraesthesia, liver enzyme and haematological changes. LOSEC can delay the elimination of phenytoin and warfarin. **PHARMACEUTICAL PRECAUTIONS:** Use within three months of opening. Store below 30°C. Replace cap firmly after use. Dispense in original container. **LEGAL CATEGORY:** POM. **FURTHER INFORMATION:** *Helicobacter pylori* (Hp) is associated with acid peptic and ulcer disease, contributing to gastritis and ulcer recurrence. In patients known to be allergic to amoxycillin, clarithromycin may be a useful alternative in dual therapy. Omeprazole 40mg daily, amoxycillin 1500mg daily

and metronidazole 1200mg daily for 14 days achieved an overall Hp eradication rate of 89% (96% in metronidazole-sensitive isolates). **PACKAGE QUANTITIES:** 10mg: bottles of 7 capsules £4.99, bottles of 28 capsules £19.95. 20mg: bottles of 7 capsules, £8.64, bottles of 28 capsules, £35.45; 40mg: bottles of 7 capsules £17.28, bottles of 14 capsules £35.45.

**PRODUCT LICENCE NUMBERS:**

PL 0017/0337 - LOSEC Capsules 10mg.  
PL 0017/0238 - LOSEC Capsules 20mg.  
PL 0017/0320 - LOSEC Capsules 40mg.

**Reference:**

1. Hallerback B, et al. 9th Asian-Pacific Congress of Gastroenterology & 6th Asian-Pacific Congress of Digestive Endoscopy, Bangkok, Thailand. Nov 29-Dec 3 1992; 90: Abstract FP-88.



For further information contact the **PRODUCT LICENCE HOLDER:** Astra Pharmaceuticals Ltd, Home Park, Kings Langley, Herts WD4 8DH. Tel: (0923) 266191. LOSEC is a registered trademark.

**Date of preparation:** September 1994

LOS/ADV 044

#### Prescribing information:

**Dipentum Presentation:** Caramel coloured capsules containing 250 mg olsalazine sodium. **Uses:** Oral treatment of acute mild ulcerative colitis and the maintenance of remission. Olsalazine consists of two molecules of 5-aminosalicylic acid (5-ASA) joined through an azo-bond. The systemic absorption of olsalazine is minimal. 99% of an oral dose will reach the colon. Olsalazine is activated in the colon where it is converted into 5-ASA. The release of 5-ASA is neither pH nor time dependent. 5-ASA acts topically on the colonic mucosa and local colonic concentrations of 5-ASA are more than 1000 times that found in the serum.

**Dosage and Administration:** *Acute Mild Disease: Adults including the Elderly.* Commence on 1g daily in divided doses and, depending upon the patient response, titrate the dose upwards to a maximum of 3g daily over 1 week. A single dose should not exceed 1g. Olsalazine should be taken with food.

**Remission: Adults including the Elderly.** Two capsules (0.5g) twice daily taken with food.

**Contra-indications: Warnings etc:**

**Contra-indications:** Hypersensitivity to salicylates. There is no experience of use of olsalazine in patients with significant renal impairment. Olsalazine is contra-indicated in patients with significant renal impairment. **Pregnancy:** Reproduction studies performed in mice, rats and rabbits have revealed no evidence of impaired fertility, harm to the foetus or teratogenic effects due to olsalazine administration. However, the experience of use in pregnant women is limited. Dipentum should not be used during pregnancy unless the clinician considers that the potential benefit outweighs the possible risk to the foetus. **Lactation:** There are no data on the excretion of olsalazine in breast milk.

**Adverse Reactions:** Watery diarrhoea has been recorded in 15% of patients treated. In half of these patients the diarrhoea was either transient or overcome by dose reduction. In patients who do not respond to dose reduction the drug should be stopped. As with sulphasalazine and mesalazine gastrointestinal side-effects are most common. The most frequently reported adverse reactions are diarrhoea, abdominal cramps, headache, nausea, dyspepsia, arthralgia and rash. **Treatment of Overdose:** There is no specific antidote to olsalazine. Treatment should be supportive.

**Pharmaceutical Precautions:** Store at room temperature in a dry place. **Legal Category:** POM.

**Package Quantities:** Containers of 100 capsules. **NHS Price:** 100 capsules £23.30.

**Further Information:** Olsalazine has been used concomitantly with glucocorticosteroids. **Product Licence Number:** 0022/0134. **Product Licence Holder:** Pharmacia Ltd., Davy Avenue, Milton Keynes MK5 8PH. **Distributed by:** Pharmacia Ltd., Davy Avenue, Milton Keynes MK5 8PH.

**References:** 1. Bjarnason J., McPherson A.J. (1993) *Inflammopharmacology*; 2: 277-287. 2. Raimundo A.H. *et al.* (1992) *Gut*; 33(1): S63. 3. Data sheet. 4. Staerk Laursen L. *et al.* (1990) *Gut*; 31(11): 1271-1276. 5. Courtney M.G. *et al.* (1992) *Lancet*; 339: 1279-81. 6. Sandberg-Gertzen H. *et al.* (1988) *Scand J Gastroenterol*; 23: Suppl. 148, 48-50.

\*coated mesalazine (Eudragit S). P/1918/494

 **Pharmacia**

Pharmacia Ltd., Davy Avenue, Milton Keynes, MK5 8PH



## Just another Dipentum day

Maximal colonic delivery of 5-ASA is what makes a Dipentum day. No other therapy is more effective in achieving this.<sup>1</sup>

Avoiding the limitations associated with variable gut pH,<sup>2</sup> compared to coated mesalazine,\* Dipentum provides; more predictable delivery,<sup>2,3,4,5</sup> lower systemic load,<sup>4</sup> greater efficacy (especially in left sided

disease)<sup>5</sup>, a highly significant patient preference<sup>5</sup> and a higher rate of remission – 76% vs 54% at 12 months.<sup>5</sup> And moreover, remission is prolonged,<sup>6</sup> raising expectations of more symptom-free days – big and small.

 **Dipentum**<sup>®</sup>  
olsalazine sodium

**Prolonging remission in ulcerative colitis**

#### **PRESCRIBING INFORMATION:**

**Indications** Duodenal ulcer, benign gastric ulcer, ulcers associated with non-steroidal anti-inflammatory drugs (NSAIDs), prevention of NSAID-associated duodenal ulcer, oesophageal reflux disease, severe oesophagitis, long-term management of healed oesophagitis, chronic episodic dyspepsia. **Dosage** *Adults:* Duodenal ulceration and gastric ulceration: A single 300mg dose at bedtime or 150mg twice daily in the morning and evening for four weeks. In duodenal ulcers, 300mg twice daily produces higher healing rates at four weeks. Continued maintenance treatment of 150mg at bedtime is recommended for patients with a history of recurrent ulceration. Ulcers following non-steroidal anti-inflammatory drug therapy or associated with continued non-steroidal anti-inflammatory drugs: 150mg twice daily for up to eight weeks. Prevention of NSAID-associated duodenal ulcer: 150mg twice daily concomitantly with NSAID therapy. Chronic episodic dyspepsia: 150mg twice daily for six weeks, investigate early relapsers and non-responders. Oesophageal reflux disease: 300mg at bedtime or 150mg twice daily for up to eight weeks. Moderate to severe oesophagitis: 150mg four times daily for up to twelve weeks (see data sheet for full dosage instructions). Long-term treatment of healed oesophagitis: 150mg twice daily. *Children:* Oral dose for peptic ulcer: 2mg/kg to 4mg/kg, twice daily to a maximum of 300mg per day. **Contra-indications** Patients with known hypersensitivity to ranitidine. **Precautions** In patients in whom sodium restriction is indicated, care should be taken when administering sodium-containing Effervescent Tablets. Exclude the possibility of malignancy in gastric ulcer before instituting therapy, especially in middle-aged patients with new or recently changed dyspeptic symptoms. Regular supervision of patients taking NSAIDs concomitantly with Zantac is recommended, especially if elderly. Protects against NSAID-associated ulceration in duodenum and not in stomach. Reduce dosage in the presence of severe renal failure (see data sheet). Avoid in patients with history of porphyria. Effervescent Tablets contain aspartame, use with caution in patients with phenylketonuria. Like other drugs, use during pregnancy and lactation only if strictly necessary. **Side effects** Headache, dizziness, skin rash, occasional hepatitis, rarely arthralgia, myalgia. Rarely, reversible mental confusion states, usually in very ill or elderly patients. Rare cases of leucopenia and thrombocytopenia, usually reversible, agranulocytosis and pancytopenia. Hypersensitivity reactions, anaphylactic shock. Rare cases of breast symptoms in men. As with other H<sub>2</sub>-receptor antagonists rare cases of bradycardia, A-V block and asystole (see data sheet). **Presentations** Zantac 150 Tablets each containing 150mg ranitidine HCl, (Product licence number 10949/0042, 60 tablets £27.89); Zantac 300 Tablets each containing 300mg ranitidine HCl (Product licence number 10949/0043, 30 tablets £27.43); Zantac Effervescent Tablets each containing 150mg ranitidine HCl and 14.3mEq sodium, (Product licence number 0004/0392, 60 tablets £27.89); Zantac Effervescent Tablets each containing 300mg ranitidine HCl and 20.8mEq sodium (Product licence number 0004/0393, 30 tablets £27.43), Zantac Syrup each 10ml dose containing 150mg ranitidine HCl (Product licence number 10949/0108, 300ml bottle £22.32). **Product licence holders** Glaxo Operations UK Limited, Greenford, Middlesex UB6 0HE. Glaxo Pharmaceuticals UK Limited, Stockley Park West, Uxbridge, Middlesex UB11 1BT. **POM** Zantac is a Glaxo trade mark. Further information is available on request from: Glaxo Laboratories Limited, Stockley Park West, Uxbridge, Middlesex UB11 1BT. Telephone 081-990 9444. June 1994.

#### **References**


1. Hayllar J, Macpherson A, Bjarnason I. Drug Safety 1992; 7(2): 86-105.
2. Rodriguez LAG, Jick H. The Lancet 1994. Vol 343: 769-772.
3. Lancaster-Smith ML, Jaderberg ME, Jackson DA. Gut 1991; 32: 252-255.
4. Robinson MG, Griffin JW, Bowers J *et al.* Dig Dis Sci 1989; 34(3): 424-428.
5. Zantac Data Sheet.

**Glaxo** Laboratories Limited

# ZANTAC STING C



# TAKING THE BIT OUT OF NSAIDs.




NSAIDs claim around 3,000 lives a year in the UK alone.<sup>1</sup> Patients with a history of ulcer disease being at greatest risk of life-threatening complications.<sup>2</sup>

However, NSAIDs also keep a great many arthritis sufferers mobile.

So, let Zantac help put an end to this sting in the tail. It's an effective treatment. Successfully healing both duodenal and gastric ulcers.<sup>3</sup> But, used as prophylaxis, Zantac can actually prevent NSAID-associated duodenal ulcers.<sup>4</sup> In fact it's the only H<sub>2</sub> licensed to do this.<sup>5</sup>

Give your high risk NSAID patients Zantac. And you can still give them the freedom of movement.



**Zantac**  
RANITIDINE HCl



# P R E D F O A M

**Unique metered dose aerosol – providing dosage uniformity<sup>1</sup>**

**Foam formulation – easier to retain than liquid preparations and preferred by patients<sup>2,3</sup>**

**Proven clinical efficacy<sup>4,5</sup>**

**Easy to use disposable applicators – clean and convenient for patients at home or at work**

**A complete local management system for maximum patient compliance**



#### **Prescribing Information**

**Predfoam** Prednisolone metasulphobenzoate sodium equivalent to 20mg prednisolone per metered dose.  
**Uses:** Treatment of proctitis and ulcerative colitis. **Dosage and administration:** Adults and elderly patients: One metered dose inserted rectally once or twice daily for two weeks, extending treatment for a further two weeks when a good response is obtained. Use should be discontinued at the discretion of the physician once the disease is stable and under control. Children: Not recommended. **Contra-indications, warnings etc.:** Contra-indications: Local conditions where infection might be masked or healing impaired, e.g. peritonitis, fistulae, intestinal obstruction, perforation of the bowel. **Precautions:** The product should be used with extreme caution in the presence of severe ulcerative colitis. The possible occurrence of masking of local or systemic infection should be borne in mind when using this product. For rectal use only. **Side-effects:** The consequences of systemic absorption should be considered with extensive use over prolonged periods. As with all rectal corticosteroids, prolonged continuous use is undesirable. **Use in pregnancy and lactation:** There is inadequate evidence of safety in human pregnancy. Topical administration of corticosteroids to pregnant animals can cause abnormalities of foetal development including cleft palate and intra-uterine growth retardation. There may, therefore, be a very small risk of such effects in the human

foetus. **Overdosage:** Overdosage by this route is unlikely. **Pharmaceutical Precautions:** Pressurised container. Protect from sunlight and do not expose to temperatures above 50°C. Do not pierce or burn even after use. Shake before use. **Legal Category:** POM. **Product Licence Number:** 0108/0101. **Product Authorisation Number:** 100/40/1. **Pack and NHS Price:** Box containing 14 fourteen dose canisters, 14 disposable nozzles and plastic bags £7.06. Full prescribing information is available on request. **Date of Preparation:** November 1993.

**References**  
1. Data on file: Pharmax. 2. K.W. Somerville, et al (1985) BMJ 291:866. 3. W.S.J. Ruddle, et al (1980) Gut 885-889. 4. C. Rodrigues, et al (1987) The Lancet, i, 1497. 5. Data on file: Pharmax.



**PHARMAX LIMITED**  
Bourne Road, Bexley, Kent DA5 1NX.  
Telephone: 0322 550550.

**PRESCRIBING INFORMATION Uses:** Adults (including the elderly): The acute treatment of nausea and vomiting of any aetiology, for up to 12 weeks treatment of nausea and vomiting due to L-dopa and bromocriptine, and for the treatment of symptoms of functional dyspepsia. Not recommended for chronic use nor, routinely, for prophylaxis of post-operative vomiting. **Children:** Only for nausea and vomiting following cancer chemotherapy or irradiation. **Presentation:** Motilium tablets (domperidone 10mg): Cartons of 30 and 100 tablets in blister strips of 10. Basic NHS cost 30 tablets: £2.46, 100 tablets: £8.21. PL 11723/0055. Motilium suspension (domperidone 1mg/ml): Bottles of 200ml. Basic NHS cost of 200ml: £1.80. PL 11723/0054. Motilium suppositories (domperidone 30mg): Cartons of 10 in blister strips of 5. Basic NHS cost 10 suppositories: £2.65. PL 11723/0051. **Dosage:** Route, dose and frequency of dosing should be adjusted according to severity and duration of symptoms. **For the treatment of nausea and vomiting** Adults (including the elderly): Tablets or suspension: 10-20mg at 4-8 hourly intervals. Suppositories: 1 or 2 at 4-8 hourly intervals. **Children:** Suspension: 0.2-0.4mg/kg at 4-8 hourly intervals. Suppositories: For children aged 2-12 years, 1-4 daily according to body weight (see Data Sheet). **For treatment of symptoms of functional dyspepsia** Adults (including the elderly): Tablets: Up to 10-20mg orally 3 times daily before meals and 10-20mg at night depending on clinical response. A course of treatment should not exceed 12 weeks. **Children:** Not recommended. **Contra-indications/Warnings, etc.:** No specific contra-indications. Safety of Motilium in pregnancy has not yet been established, therefore it should be avoided in those who are pregnant. Domperidone is excreted into breast milk but at very low levels. **Side effects:** In common with other dopamine antagonists Motilium produces a rise in serum prolactin which may be associated with e.g. galactorrhoea, and less frequently gynaecomastia, breast enlargement or soreness etc.. Domperidone does not readily cross the normally functioning blood-brain barrier. However, acute extrapyramidal dystonic reactions have been reported with Motilium, which should be treated with an anticholinergic antiparkinsonian drug, or a benzodiazepine. Occasional rashes and other allergic phenomena have been reported. Motilium is a registered trade mark. **Legal category:** POM. **Date of preparation:** March 1994.

**References:** 1. Tatsuta M *et al.* *Scand J Gastroenterol* 1989; **24** (2): 251-256. 2. De Schepper A *et al.* *Arzneimittelforsch* 1978; **28** (7): 1196-1199. 3. Bekhti A & Rutgeerts L. *Postgrad Med J* 1979; **55** (Suppl.1): 30-32. 4. Van de Akerop L *et al.* *Digestion* 1979; **19**: 244-250. 5. Sarin SK *et al.* *Indian J Med Res* 1986; **83** (June): 623-628. 6. De Loose F *et al.* (unpublished study - July 1980). 7. Agorastos I *et al.* *J Int Med Res* 1981; **9** (2): 143-147.

Further information is available on request from: Sanofi Winthrop Limited, One Onslow Street, Guildford, Surrey GU1 4YS. Telephone: (0483) 505515. Fax: (0483) 35432.



**“INDIGESTION  
BLOATING  
BELCHING  
FLATULENCE  
ABDOMINAL DISCOMFORT  
MOVE IT,  
YOU ‘ORRIBLE LOT”**

**A major force in the battle against  
recurrent non-ulcer dyspepsia**

**Motilium<sup>®</sup>**  
domperidone

**Promotes gastric emptying<sup>1,2</sup>.  
Relieves dyspeptic symptoms<sup>3-7</sup>**

**Editor: R M Donaldson Jr**  
**Contents include**

Large intestine  
Editors: V W Fazio and S F Phillips  
Gastrointestinal Infections  
Editor: S L Gorbach

Small intestine  
Editors: D H Alpers, W F Stenson &  
R Spiller  
Nutrition  
Editor: R L Fisher

Liver  
Editor: N Gitlin and J Fevery

Inflammatory bowel disease  
Editor: R P MacDermott  
Esophagus  
Editor: G N J Tytgat

Biliary tract  
Editors: J T Laont and N Afdhal  
Pancreas  
Editor: T.B.A.

Stomach and duodenum  
Editor: M.L. Schubert  
Immunology  
Editor: T.B.A.

# Current Opinion in GASTROENTEROLOGY

Each issue focuses on one or more major sections of the subject and provides a collection of highly readable, timely reviews of all significant recent developments, written by leading experts. You will be surprised how little time it takes you to stay informed.

Past issues form a unique reference to developments throughout your field. Whatever your subject of interest, you can quickly and efficiently find a description of the relevant developments, backed up by the best bibliographic information available.

Each reviewer provides a list of references and recommended reading identifying and annotating papers "of special interest", or "of outstanding interest". The selected reference list at the end of each review is supplemented by a comprehensive bibliography of literature at the back of every issue.

## BUY WITH CONFIDENCE !

We are so sure that you will want our journals in your collection that your money will be refunded if you write cancelling your order within 30 days and return to us, undamaged, all goods received.

Order form for **Current Opinion in GASTROENTEROLOGY** Volume 10, 1994, 6 issues

### Subscription

- Personal**  
☐ £74.95 / US\$124.95  
**Institutional**  
☐ £149.95 / US\$249.95  
**Pre-reg docs/Residents\***  
☐ £39.95 / US\$49.95

### Postage

- ☐ £9 (UK)  
☐ £15 (Europe)  
☐ US\$9 (North America)  
☐ US\$37 (South America)  
☐ £24 (Rest of the World)

### Payment details

- ☐ Am Ex  
☐ Visa  
☐ MasterCard  
☐ Bank Transfer \*\*\*\*  
☐ Please invoice me \*\*\*  
☐ Cheque/Eurocheque  
Payable to Current Science Ltd

### Card No.

### Exp. Date

Signature

Date

Return order form to: Current Science Ltd,  
34-42 Cleveland Street, London W1P 5FB  
Tel: (071) 323 0323 Fax: (071) 580 1938

### Electronic Database

- ☐ Please send a **FREE** demonstration disk  
☐ Windows ☐ Macintosh ☐ MS-DOS  
☐ 3½" 720kb ☐ 5¼" 360kb **Select 1**  
☐ 3½" 1.44Mb ☐ 5¼" 1.2Mb **disk type**  
☐ 3½" 800kb \*\* ☐ 3½" Superdrive \*\* **only**

### Personal details

Name

Telephone

Address

Fax

Country

Postcode

### Total amount payable

Please add postage in full

### VAT (EC only)

- \* Residents/Pre-reg doctors must provide proof of status  
... Macintosh version only  
... Institutional subscriptions only  
\*\*\*\* Current Science Ltd, Acct No. 0056750, sort 309368  
Lloyds Bank Ltd, Great Portland Street, London, W1A 4LN,  
UK. Please include details of name and address with  
payment advice. Add 20% to cover bank charges.

Certain EC customers may be liable  
to pay VAT at the applicable rate

Your VAT registration number:


Our VAT Reg. No.:  
GB466247723

For subscriptions in North and South America contact: Current Science Ltd, 20 Nth 3rd St, Philadelphia, PA19106, USA.  
For subscriptions in Japan contact: Nankodo Co. Ltd, 42-6, Hongo, 3-Chome, Bunkyo-ku, Tokyo 113 Japan



# SYSTEM THINKING

*The Complete Diagnostic GI Function Testing Lab  
Designed To Grow With You.*



**W**ith Synectics System Thinking, you can design the ideal lab for both your present and future needs, whatever they may be. Don't get locked into an inflexible and limited system that cannot grow as your patient load and procedure variety grow. All equipment from the Synectics Diagnostic Function Testing lab, including Urodynamic and Sleep Apnea Screening equipment, are designed to complement each other to create a truly comprehensive and cost effective system.




**SYNECTICS MEDICAL**

International Office • Synectics Medical AB • Renstiernas gata 12 • S-116 28 Stockholm, Sweden  
Tel: +46 8 640 23 50 • Fax: +46 8 640 54 24

**USA** • tel 1-800-227-3191 • fax 214-518-0080  
**ITALY** • tel 02-295 22 970 • fax 02-295 22 495  
**P.R. CHINA** • tel 01-491-0229 • fax 01-491 0227  
**THE NETHERLANDS** • tel 01720-76288 • fax 01720-72341  
**HUNGARY** • tel 361 250-4450 • fax 361 250-4450

**GERMANY** • tel 069-7 07 86 96 • fax 069-7 07 58 78  
**SWEDEN** • tel 08-743 08 50 • fax 08-702 03 93  
**GREAT BRITAIN** • tel 081-367 08 15 • fax 081-363 66 33  
**BELGIUM** • tel 02-674 52 63 • fax 03-658 75 67

GASTROENTEROLOGY & SLEEP APNEA SCREENING



**Digitrapper™**  
Ambulatory 24 Hour  
pH Monitoring



**MicroDigitrapper™**  
Ambulatory Esophageal and  
Antroduodenal Manometry,  
Gastric Emptying,  
Sleep Apnea Screening



**PC Poligraf**  
Ambulatory Esophageal and  
Antroduodenal Manometry,  
Gastric Emptying,  
Video Imaging



**Digitrapper™ EGG**  
Ambulatory 24 Hour  
Gastric Emptying



**Bilitec™**  
Ambulatory Bile Reflux  
Monitoring



**Bilitec™**  
Ambulatory Bile Reflux  
Monitoring



**GMI****Exhaled Hydrogen Monitor**

Hydrogen is one of the gases produced in the intestinal lumen by bacteriological breakdown of carbohydrates. The GMI Exhaled Hydrogen Monitor is designed to measure carbohydrate breakdown deficiencies and/or malabsorption.

**Patient / User Benefits**

Simple Measurement  
Non-Invasive Testing  
Recorder Print-out  
Portability  
Full Warranty  
Low Cost of Ownership

GMI Ltd, Inchinnan Estate, Renfrew, Scotland.  
Tel. 041-812-3211 Fax. 041-812-7820

## *Medical Ethics Today: Its Practice and Philosophy*

The BMA has been publishing advice on ethical issues for over forty years. This book is its most comprehensive attempt to answer the wide range of questions commonly raised and relates the long accepted standards which have governed professional behaviour to newly emerging situations.

The approach is patient-centred and the aim has been to produce a working tool for doctors whilst recognising that debate of ethical issues extends far beyond the medical profession.

ISBN 0 7279 0817 0  
374 pages 1993

UK £12.95;  
Overseas £15.95  
(BMA members  
£11.95; £14.95)

*Available from*

BMJ Publishing Group  
PO Box 295, London WC1H 9TE  
(telephone 071 383 6185/6245)

*Also available from major medical  
booksellers including the BMJ  
bookshop in BMA House*

**THIRD EDITION**

By  
**JOHN FEELY**

This fully revised third edition of *New Drugs* will help doctors to keep up to date with the latest developments in new and existing drugs.

This invaluable guide:

- Describes all drugs in common use
- Covers all of the important therapeutic advances
- Deals with specific diseases and the drugs used
- Describes adverse reactions
- Considers treatment of special groups

"A valuable review for any prescriber." *Palliative Medicine*  
"Recommended as a good buy." *Postgraduate Medical Journal*

UK £17.95; Overseas £20.00 (BMA members £16.95; £19.00)  
ISBN: 07279 0821 9 464 pages 1994

**Also available from the BMJ:**

***ABC of Monitoring Drug Therapy***

J K Aronson, M Hardman, D J M Reynolds

ISBN: 0 7279 0791 3 48 pages 1993

UK £6.95; Overseas £9.00 (BMA members £6.45; £8.50)

**ORDER FORM**

British Medical Journal, PO Box 295, London WC1H 9TE

Please send me the following books:

Qty	Title	Amount

Prices include postage by air abroad Total £

Please send me a BMJ Publishing Group catalogue ☐

Name

Address

Postcode

Cheque enclosed (made payable to British Medical Journal) £

Membership No.

Debit my AMERICAN EXPRESS/VISA/MASTERCARD

Card No.  Expiry date

Signature

BMJ books are also available at major booksellers  
or the BMJ bookshop at BMA House.

# GLYPRESSIN®

(terlipressin)

The only drug treatment shown to  
reduce B.O.V. mortality and  
improve survival rates.<sup>1,2</sup>



Bolus doses, ideal for emergency use



Rapidly controls bleeding



Earlier haemostasis improves patient's prognosis



## GLYPRESSIN®

**Abridged Prescribing Information** Name of Product: GLYPRESSIN (terlipressin). Presentation: GLYPRESSIN 1mg freeze-dried powder for injection. Supplied with 1ml ampoule of sterile diluent. **Indications:** Treatment of bleeding oesophageal varices. **Dosage and Administration:** In acute variceal bleeding, 1mg GLYPRESSIN should be administered by intravenous bolus injection followed by 1 or 2mg every 4 to 6 hours until bleeding is controlled, up to a maximum of 12 hours. **Contraindications, Warnings and Precautions:** Glypressin is contraindicated in pregnancy. The product should be used with great caution in patients with hypertension, advanced atherosclerosis, cardiac dysrhythmias or coronary insufficiency. Constant monitoring of blood pressure, serum sodium, serum potassium and fluid balance are essential. The possibility of immunological sensitisation cannot be excluded. **Side effects:** Intermittent effects include: abdominal cramps, headache, transient blindness, increase in arterial blood pressure. **Pharmaceutical precautions:** Freeze-dried powder and the diluent may be stored at room temperature, protected from direct sunlight. Each 1mg vial of GLYPRESSIN should be reconstituted with 1ml diluent supplied and used immediately. **Legal category:** Prescription Only Medicine. **Package quantity:** GLYPRESSIN (terlipressin) 1mg freeze-dried powder, single use vial. Diluent 1ml ampoule supplied with each vial. **Product Licence:** UK Product Licence number: 5194/0018. UK Product Licence holder: Terumo Pharmaceutical Ltd, Girdle House, Hatton Road, Welham, Middlesex, TW14 9PN. **Date of Preparation:** July 1991. GLYPRESSIN is a Trade Mark. **References:** 1. Soderlund C, et al. *Scand J Gastroenterol* 1990; 25:677-680. 2. Burroughs AL. *Drugs* 1992; 44(Suppl 2):11-25.

Further Information is available from: Terumo AB Box 3004, S-200 61 Malmö, Sweden.

# Statistically speaking, you're better off with a BMJ book...


## NEW REVISED EDITION

### Medical Statistics on Personal Computers

*R A Brown, J Swanson Beck*

How do you get the best out of the software available for analysing statistical data on PC's? This practical guide has been completely revised and updated and includes new chapters on survival analysis, statistical power calculations, writing up statistical analyses for medical papers, and useful notes on packages available.

**UK £10.95; Overseas £13.00**  
**(BMA members £9.95; £12.00)**  
160 pages Second edition April 1994



### Statistics in Practice

*Sheila M Gore, Douglas G Altman*

This authoritative book clearly and simply explains how to design studies, apply statistical techniques, and interpret studies using statistics.

**UK £9.95; Overseas £11.00**  
**(BMA members £7.95; £10.00)** 107 pages 1982

### Statistics at Square One

*T D V Swinscow*

The classic "beginner's guide", providing step by step instruction on the tools of the statistician such as: standard deviation, X<sup>2</sup> tests, non-parametric tests, and correlation.

**UK £4.95; Overseas £6.00**  
**(BMA members £4.45; £5.50)**  
94 pages Eighth edition 1983



### Statistics with Confidence

*Martin J Gardner,  
Douglas G Altman*

For everyone using statistical methods to present their findings, this book gives the reasons for using confidence intervals, followed by detailed methods of calculation, including numerous worked examples and specially compiled tables.

**UK £9.95; Overseas £11.00 (BMA members £8.95; £10.00)**  
156 pages 1989


### Confidence Interval Analysis (CIA)

*Martin J Gardner,  
Stephen B Gardner, Paul D Winter*

This microcomputer disk with manual takes the sweat out of calculating confidence intervals. The program can be used alone or with *Statistics with Confidence*.

Software is available for IBM compatibles on either 5¼ or a 3½ inch disk.

**UK £65.00** Educational establishments, research institutes, and the NHS: £45.95 (inc. VAT) 82 pages 1989



## ORDER FORM BMJ Publishing Group, PO Box 295, London WC1H 9TE (Tel: 071 383 6185/6245)

Qty	Book Title	Amount

Prices include postage by air abroad ☐ Please send me a BMJ Publishing Group catalogue Total £

Name

Address Postcode


Cheque enclosed (made payable to British Medical Journal) £ Membership No.

Debit my AMERICAN EXPRESS/VISA/MASTERCARD Expiry Date

Card No. Signature

BMJ Books are also available from major booksellers or the BMJ bookshop in BMA House. Book tokens accepted.

**BMJ**  
Publishing  
Group



# COLIFOAM

10% hydrocortisone acetate

## FIRST CLASS TREATMENT WHICH TRAVELS TO WORK

- ☛ Colifoam is highly effective for distal ulcerative colitis.<sup>(1)</sup>
- ☛ The retrograde spread of Colifoam increases with the extent of disease.<sup>(2)</sup>
- ☛ Colifoam is easier to retain than liquid enemas and causes less interference with social, sexual and occupational activities.<sup>(1,3)</sup>

PREScribed WITH CONFIDENCE FOR OVER 20 YEARS.



**PRESCRIBING INFORMATION:** **Presentation:** White odourless aerosol containing hydrocortisone acetate Ph Eur 10% w/w. **Uses:** Ulcerative colitis, proctosigmoiditis and granular proctitis. **Dosage and administration:** One applicatorful inserted into the rectum once or twice daily for two or three weeks and every second day thereafter. Shake can vigorously before use (illustrated instructions are enclosed with pack). **Contra-indications, warnings etc.:** Local contra-indications to the use of intrarectal steroids include obstruction, abscess, perforation, peritonitis, fresh intestinal anastomoses and extensive fistulae. General precautions common to all corticosteroid therapy should be observed during treatment with Colifoam. Treatment should be administered with caution in patients with severe ulcerative disease because of their predisposition to perforation of the bowel wall. Safety during pregnancy has not been fully established.

**Pharmaceutical precautions:** Pressurized container. Protect from sunlight and do not expose to temperatures over 50°C. Do not pierce or burn even after use. Do not refrigerate. Keep out of reach of children. For external use only. **Legal category:** POM. **Package Quantity and Basic NHS cost:** 25g canister plus applicator, £7.07. **Further Information:** One applicatorful of Colifoam provides a dose of approximately 125mg of hydrocortisone acetate, similar to that used in a retention enema, for the treatment of ulcerative colitis, sigmoiditis and proctitis. **Product Licence No.:** 0036/0021 Colifoam is a registered trade mark. **References:** 1. Somerville KW et al. BMJ 1985;291:866. 2. Farthing MJG et al. BMJ 1979;2:822-824. 3. Ruddell WSJ et al. Gut 1980;21:885-889. Further information is available on request. Stafford-Miller Ltd., Professional Relations Division, Broadwater Road, Welwyn Garden City, Herts. AL7 3SP. **Code:** DO2665.